Seres Therapeutics (MCRB) Depreciation & Amortization (CF) (2014 - 2026)

Seres Therapeutics has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $781000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 27.42% year-over-year to $781000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 23.01% YoY) and the FY2025 annual result came in at $4.1 million, down 24.41% from the prior year.
• Depreciation & Amortization (CF) eased to $781000.0 in Q1 2026 per MCRB's latest filing, from $954000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.7 million in Q3 2022 and troughed at $781000.0 in Q1 2026.
• A 5-year average of $1.4 million and a median of $1.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) increased 18.16% in 2022, then tumbled 33.52% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.6 million in 2022, then grew by 0.31% to $1.6 million in 2023, then plunged by 33.52% to $1.1 million in 2024, then retreated by 12.07% to $954000.0 in 2025, then slipped by 18.13% to $781000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $781000.0, $954000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.